Cingulate (CINGW) Change in Receivables (2021 - 2024)
Cingulate's (CINGW) quarterly Change in Receivables came in at -$12375.0 in Q1 2024, up 93.89% on a YoY basis from -$6382.5 in Q2 2023, and down 240.85% quarter-over-quarter from $8786.0 in Q4 2023.
Powered by 
Analysis
Cingulate (CINGW) Change in Receivables (2021 - 2024) Analysis & Trends
Cingulate (CINGW) has reported Change in Receivables for 4 consecutive years, with -$12375.0 the latest figure, recorded in Q1 2024.
- For the quarter ending Q1 2024, Change in Receivables rose 93.89% year-over-year to -$12375.0; the trailing twelve-month figure through Mar 2024 stood at -$29706.0 (up 95.2% YoY), and the FY2025 full-year result was -$18312.0, down 256.47% from the prior year.
- Change in Receivables fell to -$12375.0 in Q1 2024 per CINGW's latest filing, from $8786.0 in the prior quarter.
- Across five years, Change in Receivables topped out at $333186.0 in Q4 2021 and bottomed at -$511258.0 in Q2 2022.
- Historically, Change in Receivables has averaged -$11501.9 across 4 years, with a median of $3517.0 in 2023.
- The sharpest annual moves came in 2022 and 2023: Change in Receivables plunged 787.17% in 2022, then surged 100.69% in 2023.
- Over 4 years, Change in Receivables stood at $333186.0 in 2021, then tumbled by 43.85% to $187083.0 in 2022, then slumped by 95.3% to $8786.0 in 2023, then tumbled by 240.85% to -$12375.0 in 2024.
- According to Business Quant data, Change in Receivables over the past three periods registered -$12375.0, $8786.0, and -$29634.0 for Q1 2024, Q4 2023, and Q3 2023 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 644.46 Bn | 623.70 Bn | 17.26 Bn | 1.35 Bn |
| 2 | AbbVie | 440.11 Bn | 433.54 Bn | 12.70 Bn | 1.37 Bn |
| 3 | Merck | 365.04 Bn | 357.90 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 266.82 Bn | 259.13 Bn | 11.24 Bn | - |
| 5 | Pfizer | 159.14 Bn | 147.45 Bn | 10.94 Bn | - |
| 6 | Sanofi | 52.47 Bn | 45.09 Bn | 10.79 Bn | - |
| 7 | Revolution Medicines | 44.26 Bn | 44.26 Bn | - | - |
| 8 | Incyte | 25.32 Bn | 20.79 Bn | 1.57 Bn | 73.80 Mn |
| 9 | United Therapeutics | 21.46 Bn | 18.80 Bn | 683.80 Mn | -1.70 Mn |
| 10 | Cingulate | 100,214.03 | 100,214.03 | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2024 | -12,375.00 |
| Dec 31, 2023 | 8,786.00 |
| Sep 30, 2023 | -29,634.00 |
| Jun 30, 2023 | 3,517.00 |
| Mar 31, 2023 | -202,479.00 |
| Dec 31, 2022 | 187,083.00 |
| Sep 30, 2022 | -92,764.00 |
| Jun 30, 2022 | -511,258.00 |
| Mar 31, 2022 | -38,877.00 |
| Dec 31, 2021 | 333,186.00 |
| Sep 30, 2021 | 76,762.00 |
| Jun 30, 2021 | 74,400.00 |
| Mar 31, 2021 | 54,128.00 |